Twist Bioscience (TWST) is back in the spotlight after reporting fiscal second quarter revenue of US$110.72 million, 19% above the prior year, lifting full year guidance and introducing its Complex Genes early access program.

The earnings beat on revenue, higher full year guidance and Complex Genes launch have coincided with a sharp rerating, with an 83.79% year to date share price return and a very large 3 year total shareholder return, although the 5 year total shareholder return is still negative. Recent gains, including a 26.39% 3 month share price return, point to building momentum as investors reassess growth potential and execution risks in light of Twist Bioscience's AI focused partnerships and product expansion.

If this kind of AI driven biotech story interests you, it could be worth widening the lens and seeing what else is moving through a carefully curated set of 32 healthcare AI stocks

With the stock up 83.79% year to date and trading about 6% below the average analyst price target, investors now have to ask: is Twist Bioscience still mispriced, or is the market already banking on future growth?

Most Popular Narrative: 8.2% Overvalued

With Twist Bioscience closing at $59.53 against a narrative fair value of $55.00, the widely followed view now points to a premium that hinges on ambitious growth and profitability assumptions.

Expansion of Twist's customer base, especially among smaller academic clients and long-tail customers, combined with the successful rollout of new synthetic biology (SynBio) product lines, is likely to drive sustained top-line growth and broaden the company's addressable market, positively impacting future revenue.

High demand from large pharma, biotechnology, and clinical diagnostic customers for personalized medicine, genomics, and next-generation sequencing (NGS) services continues to accelerate, supported by long-term increases in global life sciences R&D investment, which should fuel ongoing revenue growth and earnings stability.

Curious what sits behind that growth story and the $55.00 fair value tag? The narrative leans on faster revenue expansion, rising margins, and a future earnings multiple that assumes Twist Bioscience earns a place alongside higher rated biotech stocks. The tension lies in how quickly losses narrow and how far profitability can scale from today’s net loss of $81.28 million.

Result: Fair Value of $55.00 (OVERVALUED)

However, there is still real execution risk from ongoing losses, including the US$81.28 million net loss, and heavy NGS customer concentration that could make revenue more volatile.

Another Way to Look at Valuation

The analyst fair value of $55.00 is based on future earnings and margins, but the current P/S ratio of 9.1x tells a different story. It sits below both peers at 19.6x and the US Biotechs average at 10.8x, yet above the 4.5x fair ratio the market could move toward. Is this a margin of safety or a premium for growth that might be hard to sustain?

To see how this pricing gap could matter for your risk and return expectations, take a closer look at the valuation breakdown in the See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

With mixed signals on value and sentiment throughout this article, the key is seeing the full picture for yourself and not relying on headlines alone. Act quickly, review both the upside and the risks, and weigh Twist Bioscience against your own risk tolerance and time horizon with the 2 key rewards and 2 important warning signs

Looking for more investment ideas?

Do not stop your research with a single stock. Broaden your watchlist now so you can spot opportunities early and avoid relying on one story.

• Spot potential bargains quickly by scanning 44 high quality undervalued stocks that pair solid fundamentals with prices the market may not fully appreciate.
• Prioritise resilience by checking 74 resilient stocks with low risk scores that score well on financial strength and business stability.
• Get ahead of the crowd by reviewing the screener containing 23 high quality undiscovered gems before they appear on everyone else's radar.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.